View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 11, 2022

Ashvattha previews plans for long Covid trial in mid-2023

In an exclusive, Ashvattha Therapeutics CEO Jeff Cleland discusses a potential trial of OP-101 in long Covid patients experiencing chronic inflammation.

By William Newton

In the constantly evolving Covid-19 landscape, a lot can change in a short time.

Two years after beginning a Phase IIa trial of OP-101 in severe Covid-19 infections, Ashvattha Therapeutics is now pivoting to long Covid with the same drug. The California-based biotech is in discussions with the FDA to run a 300–400 patient trial of OP-101 in long Covid patients beginning in mid-2023, CEO Jeff Cleland tells Clinical Trials Arena.

Although the Phase IIa trial (NCT04458298) of OP-101 reported positive results in July, Cleland says acute Covid-19 no longer makes sense as a target indication. With vaccines and antivirals now widely available in the US, it has become increasingly difficult to recruit patients with severe Covid-19 and demonstrate a significant survival benefit in trials, he explains.

The possible trial of OP-101 would target the subset of long Covid patients with chronic inflammation, Cleland says, adding that the study’s phase will depend on forthcoming regulatory discussions. Ideally, Ashvattha will only need to run one trial for an approval in long Covid, with a possible Phase IV post-marketing study commitment, he notes.

The study will select patients with elevated C-reactive protein (CRP) levels, a widely used bloodstream biomarker of inflammation, Cleland says. In the previous Phase IIa trial, OP-101 reduced CRP levels and overall inflammation in patients with severe Covid-19.

Ashvattha CEO Jeff Cleland

OP-101 is an intravenously administered hydroxyl dendrimer therapeutic, which targets reactive macrophages and microglia to reduce inflammation. By shutting down chronic inflammation in long Covid patients, OP-101 could improve lung function, fatigue, and cognitive loss, Cleland explains. OP-101 was originally developed for neurodegenerative diseases.

Long Covid endpoints

Overall, Ashvattha’s strategy will be to prioritise functional outcomes over surrogate markers, Cleland explains. The long Covid field still lacks any standardised clinical trial endpoints, making late-stage trial design a largely uncharted territory.

As a primary outcome, Ashvattha is considering lung function, which has been an approvable endpoint in idiopathic pulmonary fibrosis, Cleland says. For a possible co-primary or secondary endpoint, Ashvattha will likely use a fatigue test score, he adds.

Ashvattha will also likely include a cognitive test as a secondary outcome, Cleland says. However, this endpoint will probably not achieve statistical significance, as that would likely require close to 1,000 patients, he notes.

Long Covid describes the myriad symptoms some people experience at least one month after an acute Covid-19 infection, including breathing complications, fatigue, and brain fog. Overall, clinical trials targeting long Covid have had somewhat limited success as experts struggle to understand the condition’s underlying pathophysiology.

As Covid-19 enters an endemic state, the need for new treatments is increasing.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena